Pulmatrix (PULM) Company Report

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for Pulmatrix.

Research analysts covering Pulmatrix.

Recent press releases and 8-K filings for PULM.

Pulmatrix and Cullgen Grant Waivers to Explore Alternatives Amidst Ongoing Merger Pursuit

PULM

M&A

Guidance Update

Pulmatrix and Cullgen have mutually waived the "No Solicitation" clause in their Merger Agreement, allowing both parties to explore alternative transactions.
The companies are continuing to pursue the merger, which was approved by Pulmatrix stockholders in June 2025, but remains subject to approval from the China Securities Regulatory Commission (CSRC) and Nasdaq.
As of September 30, 2025, Pulmatrix reported $4.8 million in cash and cash equivalents, which is anticipated to fund operations into at least the fourth quarter of 2026.

Dec 18, 2025, 1:05 PM

Pulmatrix and Cullgen Waive No-Solicitation Clause Amidst Pending Merger Approval

PULM

M&A

Guidance Update

Pulmatrix and Cullgen Inc. have mutually agreed to waive the "No Solicitation" clause in their Merger Agreement, allowing both companies to explore alternate transactions while still pursuing merger approval from the China Securities Regulatory Commission (CSRC).
The merger agreement was signed in November 2024, and Pulmatrix stockholders approved the merger in June 2025, but CSRC approval is still pending.
As of September 30, 2025, Pulmatrix reported $4.8 million in cash and cash equivalents, which is anticipated to fund operations into at least the fourth quarter of 2026.

Dec 18, 2025, 1:05 PM

Pulmatrix Announces Q3 2025 Results and Divestment Plan Amidst Proposed Merger

PULM

Earnings

M&A

New Projects/Investments

Pulmatrix, Inc. announced its Third Quarter 2025 financial results and a plan to divest its migraine and inhalation assets, including its iSPERSE™ technology and Phase 2 ready acute migraine program (PUR3100), as it advances towards a proposed merger with Cullgen.
For the three months ended September 30, 2025, the company reported $0 in revenues and a net loss of $(0.877) million.
As of September 30, 2025, Pulmatrix had $4.8 million in cash and cash equivalents, which is expected to fund operations into the fourth quarter of 2026.

Oct 16, 2025, 12:05 PM

Pulmatrix Announces Q3 2025 Results and Merger-Related Divestment Plans

PULM

Earnings

M&A

Pulmatrix reported $0 in revenue for the third quarter ended September 30, 2025, a decrease from $0.4 million in the prior year period, and a net loss of $0.877 million for the quarter.
The company is advancing steps to complete a proposed merger with Cullgen, which, if consummated, would create a Nasdaq-listed company focused on targeted protein degradation technology.
As part of the proposed merger, Pulmatrix intends to divest its assets, including its proprietary iSPERSE™ dry powder delivery technology and three related clinical programs, such as the Phase 2 ready acute migraine program (PUR3100).
As of September 30, 2025, Pulmatrix had $4.8 million in cash and cash equivalents, which is anticipated to fund its operations into the fourth quarter of 2026.